文献速递肝胆胰外科围术期管理与 ERAS

胰腺癌手术中门静脉切除:血栓风险与根治性决定生存

Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival.
PubMed 文献 · Ann Surg · 2022-07-06

该单中心回顾性队列纳入2006年至2018年2265例胰腺导管腺癌(PDAC)切除患者,其中694例(30.6%)联合门静脉切除(PVR)。PVR后90天死亡率为6.3%,高于标准切除的2.6%;移植间置重建者术后门静脉血栓和胰腺特异性并发症发生率最高。多变量分析显示PVR等为总生存的负性预后因素,但达到根治性R0(>1 mm)切除时中位生存达23.3个月。

要点

  • PVR联合胰腺切除占PDAC手术30.6%,90天死亡率高于标准切除(6.3% vs 2.6%)。
  • 移植间置重建(ISGPS 4型)术后门静脉血栓和胰腺特异性并发症发生率最高。
  • 达到根治性R0(>1 mm)切除时中位生存近2年,血栓风险被生存获益抵消。

核心结论

  • PVR术后并发症与重建类型相关,达到根治性切除时血栓风险被近2年的总生存获益所抵消。

研究设计与样本

  • 单中心对比队列研究,纳入2006年1月至2018年1月连续手术的2265例PDAC切除患者。

主要发现

  • 1571例(69.4%)为标准切除,694例(30.6%)联合PVR,其中ISGPS 1型149例(21.5%)、2型21例(3.0%)、3型491例(70.7%)、4型33例(4.8%)。
  • 标准切除后90天死亡率为2.6%,PVR后为6.3%(P<0.0001)。
  • 移植间置重建(4型)后门静脉血栓发生率为21.2%,胰腺特异性手术并发症发生率为48.5%。
  • 多变量分析中,年龄≥70岁、ASA 3/4级、术前血清CA19-9升高、新辅助治疗、全胰腺切除、PVR、较高UICC分期和R+切除为总生存的显著负性预后因素。
  • 根治性R0(>1 mm)切除的中位生存为23.3个月。

临床怎么用

  • PVR联合胰腺切除时需根据重建类型(尤其4型移植间置)警惕门静脉血栓和胰腺特异性并发症。
  • 应争取达到根治性R0(>1 mm)切除,以获取近2年的中位生存获益。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). BACKGROUND: Surgery offers the only chance for cure in PDAC. PVR is often performed for borderline or locally advanced tumors. METHODS: Consecutive patients with PDAC operated between January 2006 and January 2018 were included. Clinicopathologic characteristics and outcomes were analyzed and tested for survival prediction. RESULTS: Of 2265 PDAC resections, 1571 (69.4%) were standard resections and 694 (30.6%) were resections with PVR, including 149 (21.5%) tangential resections with venorrhaphy (ISGPS type 1), 21 (3.0%) resections with patch reconstruction (type 2), 491 (70.7%) end-to-end anastomoses (type 3), and 33 (4.8%) resections with graft interposition (type 4). The 90-day mortality rate was 2.6% after standard resection and 6.3% after resection with PVR ( P <0.0001). Postoperative portal vein thrombosis and pancreas-specific surgical complications most frequently occurred after PVR with graft interposition (21.2% and 48.5%, respectively). In multivariable analysis, age 70 years and above, ASA stages 3/4, increased preoperative serum carbohydrate antigen 19-9, neoadjuvant treatment, total pancreatectomy, PVR, higher UICC stage, and R+ resections were significant negative prognostic factors for overall survival. Radical R0 (>1 mm) resection resulted in 23.3 months of median survival. CONCLUSIONS: This is the largest single-center, comparative cohort study of PVR in PDAC surgery, showing that postoperative morbidity correlates with the reconstruction type. When radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Hackert T, Klaiber U, Hinz U, et al. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival. Ann Surg. 2022. PMID: 35793384. doi:10.1097/SLA.0000000000005444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。